DOP2010000301A - Compuestos de anillo fusionados y uso de los mismos - Google Patents

Compuestos de anillo fusionados y uso de los mismos

Info

Publication number
DOP2010000301A
DOP2010000301A DO2010000301A DO2010000301A DOP2010000301A DO P2010000301 A DOP2010000301 A DO P2010000301A DO 2010000301 A DO2010000301 A DO 2010000301A DO 2010000301 A DO2010000301 A DO 2010000301A DO P2010000301 A DOP2010000301 A DO P2010000301A
Authority
DO
Dominican Republic
Prior art keywords
fusioned
same
ring compounds
provides
present
Prior art date
Application number
DO2010000301A
Other languages
English (en)
Inventor
Nobuyuki Takakura
Tsuneo Yasuma
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of DOP2010000301A publication Critical patent/DOP2010000301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención proporciona un activador de glucocinasa útil como un agente farmacéutico tal como un agente para la profilaxis o tratamiento de diabetes, obesidad y similares. La presente invención proporciona un activador de glucocinasa que contiene un compuesto representado por la formula (I): en donde cada símbolo se define en la especificación, o una sal del mismo o un Pro fármaco del mismo.
DO2010000301A 2008-04-10 2010-10-08 Compuestos de anillo fusionados y uso de los mismos DOP2010000301A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008102691 2008-04-10

Publications (1)

Publication Number Publication Date
DOP2010000301A true DOP2010000301A (es) 2010-12-31

Family

ID=40671202

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000301A DOP2010000301A (es) 2008-04-10 2010-10-08 Compuestos de anillo fusionados y uso de los mismos

Country Status (35)

Country Link
US (1) US8673942B2 (es)
EP (1) EP2276760B1 (es)
JP (1) JP5528348B2 (es)
KR (1) KR20110002472A (es)
CN (1) CN102056924B (es)
AR (1) AR073609A1 (es)
AU (1) AU2009234666B2 (es)
BR (1) BRPI0910912A2 (es)
CA (1) CA2720686A1 (es)
CO (1) CO6321240A2 (es)
CR (1) CR11730A (es)
CY (1) CY1115247T1 (es)
DK (1) DK2276760T3 (es)
DO (1) DOP2010000301A (es)
EA (1) EA019640B1 (es)
EC (1) ECSP10010602A (es)
ES (1) ES2476265T3 (es)
GE (1) GEP20135846B (es)
HK (1) HK1152932A1 (es)
HR (1) HRP20140588T1 (es)
IL (1) IL208463A (es)
MA (1) MA32283B1 (es)
ME (1) ME01887B (es)
MX (1) MX2010011138A (es)
MY (1) MY152475A (es)
NZ (1) NZ588562A (es)
PE (1) PE20100734A1 (es)
PL (1) PL2276760T3 (es)
PT (1) PT2276760E (es)
RS (1) RS53378B (es)
SI (1) SI2276760T1 (es)
UA (1) UA104422C2 (es)
UY (1) UY32131A (es)
WO (1) WO2009125873A1 (es)
ZA (1) ZA201007682B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
EP2931734B1 (en) * 2012-12-17 2020-12-02 Merck Sharp & Dohme Corp. Novel glucokinase activator compounds, compositions containing such compounds, and methods of treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015301A1 (en) 1991-03-01 1992-09-17 H. Lundbeck A/S Treatment of hypertension and peripheral vascular diseases
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
EA008769B1 (ru) 2002-06-05 2007-08-31 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения диабета
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
EP1853255A4 (en) 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS
EP2308839B1 (en) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
CN101801965B (zh) * 2007-08-17 2014-07-30 株式会社Lg生命科学 作为细胞坏死抑制剂的吲哚化合物
RU2450001C2 (ru) 2007-12-20 2012-05-10 Эл Джи Лайф Сайенсиз Лтд. Активаторы глюкокиназы и фармацевтические композиции, содержащие их в качестве активного ингредиента
US20100291533A1 (en) 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE

Also Published As

Publication number Publication date
BRPI0910912A2 (pt) 2015-08-11
EA201071180A1 (ru) 2011-04-29
CO6321240A2 (es) 2011-09-20
SI2276760T1 (sl) 2014-05-30
US8673942B2 (en) 2014-03-18
EA019640B1 (ru) 2014-05-30
CA2720686A1 (en) 2009-10-15
HRP20140588T1 (hr) 2014-08-01
CN102056924A (zh) 2011-05-11
PT2276760E (pt) 2014-05-28
GEP20135846B (en) 2013-06-10
CN102056924B (zh) 2014-05-21
ES2476265T3 (es) 2014-07-14
ZA201007682B (en) 2011-12-28
JP2011516403A (ja) 2011-05-26
EP2276760B1 (en) 2014-04-09
KR20110002472A (ko) 2011-01-07
IL208463A0 (en) 2010-12-30
CR11730A (es) 2010-12-08
UY32131A (es) 2010-11-30
WO2009125873A1 (en) 2009-10-15
PE20100734A1 (es) 2010-11-18
NZ588562A (en) 2012-07-27
AR073609A1 (es) 2010-11-17
PL2276760T3 (pl) 2014-09-30
IL208463A (en) 2015-07-30
MA32283B1 (fr) 2011-05-02
EP2276760A1 (en) 2011-01-26
DK2276760T3 (da) 2014-05-26
CY1115247T1 (el) 2017-01-04
AU2009234666B2 (en) 2014-02-20
ECSP10010602A (es) 2011-03-31
MX2010011138A (es) 2010-11-12
ME01887B (me) 2014-12-20
JP5528348B2 (ja) 2014-06-25
MY152475A (en) 2014-10-15
HK1152932A1 (en) 2012-03-16
US20110098297A1 (en) 2011-04-28
UA104422C2 (uk) 2014-02-10
RS53378B (en) 2014-10-31
AU2009234666A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
DOP2010000301A (es) Compuestos de anillo fusionados y uso de los mismos
ECSP099330A (es) Compuesto de indol
CR10564A (es) Compuestos cíclicos fusionados
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
DOP2010000267A (es) Compuesto heterociclico
UY30759A1 (es) Compuestos quimicos
ECSP13012719A (es) Compuesto bicíclico
CO6511251A2 (es) Compuestos quimicos
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
UY33547A (es) COMPUESTOS QUÍMICOS Bcl-2 y Bcl-XL
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
ECSP099620A (es) Derivados de ciclohexano espirociclico
BR112012032087A2 (pt) composto, medicamento, e, uso de um composto
BR112014022214A2 (pt) fenólicos antibacterianos
ECSP099776A (es) Moduladores de la gamma secretasa
ECSP11011558A (es) Nuevos compuestos químicos.
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
CL2008003639A1 (es) Compuestos derivados de amida; composición farmacéutica que comprende a dicho compuesto; combinación farmacéutica; y uso del compuesto en el tratamiento del vih.
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332